Skip to main content

Table 1 Demographic data and clinical characteristics

From: Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B

Characteristic

n = 91

Baseline (end of treatment)

 Age, years

35.7 ± 7.9

 Sex (Male: Female)

75:16

 First-line NA therapy a

39 (42%)

 Therapy duration, years

56.7 ± 26.2

 Consolidation therapy duration, months

28 (18–46)

 ALT level, × ULN

0.5 (0.4–0.7)

ALT elevation, n (%)

 < ULN

78 (86%)

 ULN-2 × ULN

12 (13%)

 HBV DNA level, log10 IU/ml

UD

 HBsAg level, log10 IU/ml

2.9 (2.3–3.3)

 < 100 IU/ml

20 (22%)

 100–1000 IU/ml

31 (34%)

 > 1000 IU/ml

40 (44%)

Start of treatment

 HBeAg status (Positive: Negative)

61:30

 ALT elevation ×ULN

5.33 ± 4.29

 HBV DNA log10 IU/ml

6.20 ± 1.41

  1. Quantitative variables are expressed as mean values ± standard deviation (range) or median values (range). ALT Alanine aminotransferase, HBsAg Hepatitis B surface antigen, HBV Hepatitis B virus, NA Nucleos(t)ide analogue, UD Undetectable (< 20 IU/ml), ULN Upper limit of normal
  2. aFirst-line: entecavir, tenofovir